GSK Q2 2026 core operating profit rises 7% on specialty medicines strength

GSK plc (LSE: GSK; NYSE: GSK) reported second-quarter 2026 results on 28 July that framed the group as two very different businesses inside a single P&L: a specialty medicines and vaccines engine growing at high single to double-digit rates, and a general medicines base still in managed decline. Turnover rose 5 per cent at both actual exchange rates and constant exchange rates to £8.4 billion, core operating profit rose 7 per cent to £2.8 billion, and core earnings per share rose 9 per cent to 50.5 pence, all above the pre-print sell-side path. The optical shock came in total results, where operating profit fell 75 per cent and total earnings per share fell 69 per cent, driven primarily by a £1.3 billion impairment on camlipixant and higher contingent consideration liability charges. Chief Executive Officer Luke Miels used the print to signal a step-up in research and development commitment, including 20-plus phase III trial starts in 2026, a new flagship R&D centre on the Cambridge Biomedical Campus, and a three-year cost programme targeting £1.9 billion of annual savings by 2029 to fund the reinvestment. The central tension is whether the specialty and vaccines momentum, together with the recently closed Nuvalent lung cancer acquisition, can carry the group to its 2031 sales outlook of more than £40 billion while margins absorb accelerating R&D spend and the dolutegravir loss-of-exclusivity window from 2028 to 2030.

What did GSK actually deliver in Q2 2026 and why is the market focused on core rather than total profit?

Group turnover of £8.4 billion for the quarter came with a clean 5 per cent growth number at both reporting conventions, but the mix inside that figure is what will drive the investment case for the next several quarters. Specialty medicines sales of £3.8 billion grew 14 per cent, with respiratory, immunology and inflammation up 19 per cent to £1.1 billion, oncology up 17 per cent to £0.6 billion, and HIV up 10 per cent to £2.1 billion. Vaccines revenue of £2.3 billion grew 8 per cent, with meningitis vaccines up 21 per cent to £0.5 billion, Arexvy more than doubling to £0.2 billion, and Shingrix delivering low single-digit growth to £0.9 billion. General medicines sales fell 9 per cent to £2.3 billion, with Trelegy down 7 per cent to £0.8 billion under US Medicare pricing pressure and competitive intensity. Cash generated from operations rose 19 per cent to £2.9 billion and free cash flow reached £2.0 billion in the quarter, with core operating margin expanding to 33.3 per cent, up 60 basis points at constant exchange rates.

The reason the sell side and buy side have both anchored commentary on core rather than total metrics is that the £1.3 billion camlipixant impairment and £371 million Alector collaboration termination charge are unusually large but analytically discrete items tied to specific development decisions. Company management directed investors to core operating profit growth of 7 per cent, core earnings per share growth of 9 per cent and a first-half core operating margin of 34.0 per cent, up 120 basis points at constant exchange rates, as the metrics that reflect underlying operating performance.

How does the £1.3 billion camlipixant impairment reshape the group’s chronic cough franchise thesis?

GSK plc confirmed in the release that it will not progress further development of camlipixant in refractory chronic cough following the aggregate data from the CALM-1 and CALM-2 phase III trials. The recoverable amount of camlipixant is stated at £104 million based on value in use for the irritable bowel syndrome indication, which is the carrying value as at 30 June 2026. This effectively takes what was previously flagged as one of GSK’s higher-value pipeline assets out of the chronic cough narrative and reduces the franchise ambition tied to the 2018 acquisition of the underlying programme.

The financial write-down is now recognised, but the strategic consequence is that GSK plc no longer has a leading late-stage differentiated asset in refractory chronic cough, an indication where competitor progress has been variable and where the commercial opportunity had been core to the specialty medicines expansion thesis. Management framed the decision as evidence of disciplined portfolio management, and it will be judged against how quickly the seven identified asset accelerations and 20-plus phase III trial starts translate into replacement optionality.

Why does the £7.1 billion Nuvalent acquisition matter more for non-small cell lung cancer than for headline financials?

Management confirmed on the results call that the Nuvalent acquisition completed on 15 July 2026 at a net cost of £7.1 billion, taking net debt to £22 billion, or just under 2 times net debt to 2025 core earnings before interest, taxes, depreciation and amortisation. The transaction adds two late-stage non-small cell lung cancer medicines to the oncology franchise: Jideytro, which has received US Food and Drug Administration approval, and neladalkib, which has a Prescription Drug User Fee Act target action date in the second half of 2026. Both assets target defined molecular subsets in non-small cell lung cancer, an indication where GSK plc had been under-weighted relative to peers in solid tumour oncology.

The reason Jideytro and neladalkib matter more than the headline financials in the near term is that they give the enlarged oncology unit a foothold in the two most commercially attractive non-small cell lung cancer segments. When combined with the positive phase III overall survival data from partner Hansoh in China for Ris-Rez, a B7-H3 targeted antibody-drug conjugate that GSK plc management described as the first positive phase III overall survival readout for the target class in any tumour type, the oncology unit now has a credible late-stage lung cancer stack. The trade-off is that additional interest expense of around £160 million tied to the Nuvalent funding pushed core EPS guidance for 2026 to the lower half of the 7 to 9 per cent range even as turnover and core operating profit guidance shifted towards the upper half of their respective ranges.

How does the seven-asset acceleration and 20-plus phase III starts change the R&D risk profile through 2031?

GSK plc identified seven asset accelerations across 18 indications spanning oncology, respiratory, hepatology and vaccines. The company now expects 20-plus phase III trial starts in 2026, roughly double its previous plan of 10. Named late-stage assets flagged in the release include the ongoing Ris-Rez lung cancer programme, Jemperli in advanced rectal cancer following positive AZUR-1 data, Ojjaara (momelotinib) following recent Orphan Drug Designations in the US and European Union for VEXAS syndrome, and bepirovirsen for chronic hepatitis B, where pivotal data showed what management described as unprecedented functional cure rates.

The consequence for the risk profile is asymmetric. On one hand, the group is materially widening the number of independent phase III readouts feeding into the 2028 to 2031 period, which is the single most useful way to offset a large late-decade loss-of-exclusivity event. On the other hand, doubling the phase III cadence in a year mechanically increases the probability that at least one high-visibility programme fails, as camlipixant did, with an associated non-cash but material total-results impact. Investors should track whether the 2027 and 2028 phase III readout schedules include indications with reproducibly validated targets and whether the operating margin path can absorb an elevated R&D spend without breaching the “stable to improving” commitment made for the dolutegravir loss-of-exclusivity window.

What does the three-year £1.9 billion cost programme actually fund inside the pipeline reinvestment plan?

The Accelerate Growth cost programme is targeted at £1.9 billion of annual savings by 2029, at a total programme cost of £2.4 billion, of which £2.1 billion is cash. Management was explicit that the savings will primarily be reinvested into the late-stage portfolio and R&D acceleration, with some proportion used to defend margins through the 2028 to 2030 period. The programme is being framed as a simplification of the organisation and reallocation of capital and resources rather than a stand-alone margin defence exercise.

The commercial implication is that GSK plc has chosen to fund its pipeline acceleration from internal cost action rather than by leaning further on shareholder returns or by holding R&D flat and letting margins drift up. Management pointed to a completed £2 billion share buyback executed at an average price of £16.13 over 18 months, alongside a Q2 dividend of 17 pence per share and an expected full-year 2026 dividend of 70 pence. The result is a policy stance that treats reinvestment, dividend and buyback as sequenced rather than competing uses of cash, and that positions the £1.9 billion savings run rate as the pivot around which the 2028 to 2031 margin story is anchored.

How is the specialty medicines and vaccines mix now offsetting the drag from Trelegy and general medicines?

The 14 per cent growth in specialty medicines and 8 per cent growth in vaccines mathematically offset the 9 per cent decline in general medicines and left group turnover growth at 5 per cent for the quarter. The composition is more important than the arithmetic. Meningitis vaccines growth of 21 per cent, driven in part by the newer Penbraya and Bexsero contribution, and the more than 100 per cent expansion of Arexvy following its expanded approval in Japan for adults aged 18 to 59 at increased risk of respiratory syncytial virus, mean the vaccines franchise is no longer dependent on Shingrix carrying the entire growth burden. Management upgraded the full-year 2026 vaccines guide from a previously expected decline to “broadly stable to a low single-digit increase”.

The trade-off is that Trelegy remains the single largest general medicines exposure, and the 7 per cent decline reflects a combination of US Medicare pricing changes and generic and branded competition that is unlikely to reverse. Investors should read the general medicines line as a slowly amortising legacy contribution to group cash flow rather than a growth engine, which places even more weight on the specialty and vaccines mix delivering the mid-teens contribution that the 2031 outlook implies.

Why does the 2028-2030 dolutegravir loss of exclusivity remain the single largest execution overhang?

Dolutegravir, marketed as Tivicay and as the backbone of the ViiV Healthcare HIV portfolio, is expected to enter a loss-of-exclusivity window between 2028 and 2030. GSK plc holds a 78.3 per cent economic interest in ViiV Healthcare following the completion of the ownership transaction with Shionogi in March 2026, in which Shionogi acquired 21.7 per cent for $2.125 billion. HIV sales of £2.1 billion in Q2, up 10 per cent, remain the single largest specialty medicines franchise.

Management reiterated that operating margin is expected to be stable to improving through the dolutegravir loss-of-exclusivity period. That commitment is essentially the reason the £1.9 billion cost programme, the specialty pipeline acceleration and the Nuvalent transaction are being executed on the current timeline. If the phase III cadence delivers, if the ViiV oral and long-acting portfolio replacement pipeline maintains competitive positioning, and if general medicines decline stays contained, the group can absorb dolutegravir erosion without a step-down in margin. If any one of those legs slips, the 2028 to 2030 period becomes a materially harder margin defence problem than the current guidance implies.

How does the market reaction to Q2 fit against the current £84 billion market capitalisation and pre-results consensus?

GSK plc ordinary shares closed at 1,961.00 pence on the London Stock Exchange on 27 July 2026 and opened the results morning at 1,969.50 pence, with reports indicating a gain of around 3.35 per cent on 28 July as the market processed the beat and the guidance mix. The 52-week range stands at 1,360.50 to 2,282.00 pence, and the LSE snapshot on 28 July placed instrument market capitalisation at approximately £84.6 billion. The stock is a FTSE 100 constituent and the American Depositary Shares trade on the New York Stock Exchange under the same GSK ticker.

The market response was positive, although the longer-term valuation still depends on execution against the 2031 sales outlook. Business News Today did not identify a widely published current broker consensus that has fully absorbed both the Nuvalent close and the updated cost programme, so the pre-print consensus should be treated as partially stale until brokers update models. The relevant valuation questions remain whether the specialty medicines and vaccines growth rates can compound at the current pace through 2028, and whether the acceleration in R&D spend translates into replacement products by the point at which dolutegravir revenue begins to erode.

What key catalysts should investors track between now and full-year 2026 results?

The near-term catalyst set is unusually concentrated. In the second half of 2026, investors should watch the PDUFA target action date for neladalkib in non-small cell lung cancer, regulatory reviews for Jemperli in advanced rectal cancer following AZUR-1, further phase III readouts in the accelerated pipeline, and progress of the bepirovirsen chronic hepatitis B programme towards regulatory filing. Investors should also watch for detail on the Cambridge Biomedical Campus R&D centre, which was flagged as a flagship investment but for which capital commitment and phasing were not disclosed in the Q2 release.

On the financial side, the Q3 2026 print will provide the first clean look at post-Nuvalent net debt trajectory, interest expense phasing, and whether specialty medicines and vaccines momentum has held into the second half. Full-year 2026 results will show whether GSK plc has delivered turnover and core operating profit at the upper half of the 3 to 5 per cent and 7 to 9 per cent ranges respectively, and whether core EPS lands in the lower half of the 7 to 9 per cent range as newly guided.

What should investors track as GSK plc executes the £1.9bn cost programme through the 2031 sales delivery window?

• Turnover of £8.4 billion in Q2 grew 5 per cent at constant exchange rates, with specialty medicines up 14 per cent, vaccines up 8 per cent, and general medicines down 9 per cent, confirming the two-speed nature of the business.
• Core operating profit rose 7 per cent to £2.8 billion and core earnings per share rose 9 per cent to 50.5 pence, with first-half core operating margin at 34.0 per cent, up 120 basis points at constant exchange rates.
• Total operating profit fell 75 per cent and total EPS fell 69 per cent, driven by a £1.3 billion camlipixant impairment and higher contingent consideration liability charges, with camlipixant now carried at £104 million on the value-in-use basis for irritable bowel syndrome.
• The Nuvalent acquisition completed on 15 July 2026 at a net cost of £7.1 billion, taking net debt to approximately £22 billion, or just under 2 times net debt to 2025 core EBITDA, and adds Jideytro and neladalkib to the non-small cell lung cancer franchise.
• Full-year 2026 guidance was reaffirmed with turnover expected at 3 to 5 per cent growth at the upper half of the range, core operating profit at 7 to 9 per cent at the upper half, and core EPS at 7 to 9 per cent at the lower half, with vaccines guidance upgraded to broadly stable to low single-digit growth.
• The three-year cost programme targets £1.9 billion of annual savings by 2029 for £2.4 billion of costs, £2.1 billion of which is cash, primarily to fund late-stage portfolio acceleration and to defend margins into the dolutegravir loss-of-exclusivity period.
• Pipeline acceleration includes seven asset accelerations across 18 indications, 20-plus phase III trial starts in 2026 versus a previous 10, positive AZUR-1 data for Jemperli in advanced rectal cancer, positive phase III overall survival data from Hansoh for Ris-Rez in lung cancer, and pivotal data for bepirovirsen in chronic hepatitis B.
• A new flagship R&D centre will be established on the Cambridge Biomedical Campus, integrating GSK plc into one of the most active life sciences ecosystems, although capital commitment and phasing were not disclosed with the Q2 print.
• The 2031 sales outlook of more than £40 billion remains the primary long-term test, with operating margin guided as stable to improving through the 2028 to 2030 dolutegravir loss-of-exclusivity period, contingent on phase III execution and specialty and vaccines momentum being sustained.
• The Q2 dividend of 17 pence per share was declared, the full-year 2026 dividend is expected at 70 pence, the £2 billion share buyback is complete at an average price of £16.13, and the next major catalyst set is centred on the neladalkib PDUFA in H2 2026, the Q3 2026 print, and the Cambridge R&D centre detail.